On Monday, Janux Therapeutics Inc (NASDAQ: JANX) opened lower -5.14% from the last session, before settling in for the closing price of $64.99. Price fluctuations for JANX have ranged from $7.79 to $71.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 32.66%. Company’s average yearly earnings per share was noted -6.60% at the time writing. With a float of $42.68 million, this company’s outstanding shares have now reached $52.34 million.
Let’s determine the extent of company efficiency that accounts for 64 employees. In terms of profitability, gross margin is 87.98%, operating margin of -658.76%, and the pretax margin is -463.91%.
Janux Therapeutics Inc (JANX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Janux Therapeutics Inc is 18.68%, while institutional ownership is 86.65%. The most recent insider transaction that took place on Dec 03 ’24, was worth 1,005,000. In this transaction President and CEO of this company sold 15,000 shares at a rate of $67.00, taking the stock ownership to the 242,054 shares. Before that another transaction happened on Nov 25 ’24, when Company’s President and CEO sold 25,000 for $51.60, making the entire transaction worth $1,289,879. This insider now owns 257,054 shares in total.
Janux Therapeutics Inc (JANX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -6.60% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Check out the current performance indicators for Janux Therapeutics Inc (JANX). In the past quarter, the stock posted a quick ratio of 38.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 267.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.97 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Looking closely at Janux Therapeutics Inc (NASDAQ: JANX), its last 5-days average volume was 3.7 million, which is a jump from its year-to-date volume of 0.78 million. As of the previous 9 days, the stock’s Stochastic %D was 76.66%. Additionally, its Average True Range was 5.57.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 72.96%, which indicates a significant increase from 68.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 187.52% in the past 14 days, which was higher than the 85.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $51.28, while its 200-day Moving Average is $46.11. However, in the short run, Janux Therapeutics Inc’s stock first resistance to watch stands at $64.24. Second resistance stands at $66.83. The third major resistance level sits at $68.37. If the price goes on to break the first support level at $60.11, it is likely to go to the next support level at $58.57. Should the price break the second support level, the third support level stands at $55.98.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
There are currently 52,482K shares outstanding in the company with a market cap of 3.49 billion. Presently, the company’s annual sales total 8,080 K according to its annual income of -58,290 K. Last quarter, the company’s sales amounted to 440 K and its income totaled -28,060 K.
